Search

Heron Therapeutics Inc

Lezárt

SzektorEgészségügy

0.35 6.06

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

0.3

Maximum

0.36

Fő mutatók

By Trading Economics

Bevétel

2.6M

-5.5M

Értékesítés

3M

38M

Egy részvényre jutó nyereség

-0.03

Profit margin

-14.573

Munkavállalók

128

EBITDA

2.1M

-5.5M

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 3.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-33M

63M

Előző nyitás

-5.71

Előző zárás

0.35

Hangulat hírek alapján

By Acuity

81%

19%

315 / 340 Rangsor szerint Healthcare

Heron Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 12. 23:56 UTC

News

Allegro Microsystems shares rose in after-market trading following Benchmark's initiation of coverage with a Buy rating. The stock closed at $42.52.

2026. aug. 12. 23:56 UTC

Social Media
News

STAAR Surgical shares are lower in after-market hours following an EPS miss, despite reporting second-quarter net sales of $93.5 million, a 111% increase.

2026. aug. 12. 23:51 UTC

News

Fossil Group Inc reported second-quarter sales of $209.7 million, exceeding expectations. Shares are trading sharply higher in after-market hours.

2026. aug. 12. 23:51 UTC

Social Media
News

PTC Therapeutics acquires ST-920 gene therapy for $111 million, enhancing its rare disease portfolio. Shares are higher in after-market hours.

2026. aug. 12. 23:51 UTC

Social Media
News

Harmonic Inc. reported strong Q2 results, with adjusted EPS of $0.24 and raised full-year guidance, leading shares higher in after-market hours.

2026. aug. 12. 23:51 UTC

News
Social Media

Omeros Corp reported second-quarter revenues of $32.2 million, exceeding expectations. Shares rose in after-market trading following the strong financial results and Medicare approval.

2026. aug. 12. 23:46 UTC

News

Cummins shares are higher in after-market trading following strong Q2 earnings of $9.46 billion, surpassing analyst expectations despite an adjusted EPS miss.

2026. aug. 12. 23:46 UTC

News

Wendy's shares declined in after-market hours after earlier gains on news of a potential buyout bid from Nelson Peltz's Trian Fund Management.

2026. aug. 12. 23:41 UTC

News

Granite Construction secures a $31 million contract for the Willow Rock Energy Storage Center, boosting its project portfolio. Shares are higher in after-market trading.

2026. aug. 12. 23:41 UTC

News

Mistras Group raised its fiscal year revenue guidance to $740-$755 million, driving shares higher in after-market trading. Adjusted EBITDA is expected around $93.5 million.

2026. aug. 12. 23:41 UTC

News
Social Media

Jack in the Box Inc. reports third-quarter earnings with EPS of $1.08, exceeding expectations. The stock is trading higher in after-market hours.

2026. aug. 12. 23:41 UTC

Social Media
News

EnerSys reported strong first-quarter results, with adjusted EPS of $3.66 and revenue of $935.6 million. Shares are higher in after-market trading.

2026. aug. 12. 23:41 UTC

News
Social Media

Coherent Corp shares fell in after-hours trading despite strong fourth-quarter results, including adjusted EPS of $1.74 and revenue of $2.05 billion.

2026. aug. 12. 23:41 UTC

Social Media
News

Enovix Corp shares are lower in after-market hours following mixed second-quarter results and lower-than-expected third-quarter revenue guidance.

2026. aug. 12. 23:36 UTC

Social Media
News

Cheniere Energy raised its 2026 earnings and production guidance despite a quarterly loss. Shares are higher in after-market trading amid rising natural gas prices.

2026. aug. 12. 23:36 UTC

News

Alexandria Real Estate Equities has priced a $1 billion offering of 7.250% junior subordinated notes, with shares modestly higher in after-market trading.

2026. aug. 12. 23:36 UTC

News

Nasdaq Inc. shares gained in after-market trading, reaching a monthly high as inflation data eased concerns over Federal Reserve rate hikes.

2026. aug. 12. 23:26 UTC

News

Red Robin Gourmet Burgers shares rose in after-market trading following a Q2 earnings report that showed adjusted earnings and revenue exceeding analyst expectations.

2026. aug. 12. 23:26 UTC

News

Trian Fund Management increased its stake in GE Healthcare Technologies to 3.1 million shares, contributing to a modest rise in after-market hours.

2026. aug. 12. 23:26 UTC

News
Correlated Moves

Vishay Intertechnology announced a quarterly dividend of $0.10 per share, enhancing investor sentiment as shares trade higher in after-market hours.

2026. aug. 12. 23:21 UTC

News

Duke Energy has restored power to over 171,000 customers in Greater Cincinnati. Shares are gaining in after-market hours amid this progress.

2026. aug. 12. 23:21 UTC

News

Allogene Therapeutics reports narrower net loss of $42.7 million, revenue of $4.64 million. Shares higher after positive trial results and $500 million securities offering announcement.

2026. aug. 12. 23:11 UTC

News

Goldman Sachs will acquire NEOS Investments for up to $2.25 billion, enhancing its asset management division with new income ETFs. Shares are higher in after-market trading.

2026. aug. 12. 23:06 UTC

News

Spero Therapeutics reports FDA approval of Utebzi and secures $105 million financing. Shares are trading higher in after-market hours.

2026. aug. 12. 23:06 UTC

News
Social Media

Meta Platforms faces a federal trial over youth safety violations. In after-market trading, shares are slightly higher despite ongoing legal challenges.

2026. aug. 12. 23:06 UTC

News

Phillips 66 shares rose in after-market trading following a strong second-quarter performance and a $10 billion increase in buyback authorization.

2026. aug. 12. 23:06 UTC

News

FormFactor Inc will participate in key investor conferences, boosting market interest. Shares are higher in after-market trading following the announcement.

2026. aug. 12. 23:06 UTC

Social Media
News

NextEra Energy has secured a $3.3 billion investment for natural gas projects in Texas and Pennsylvania, though shares are trading lower in after-market hours.

2026. aug. 12. 23:02 UTC

Social Media
News

Pfizer shares rose after Chairman Albert Bourla bought 38,000 shares at $26.34, totaling about $1 million, signaling confidence in the company's prospects.

2026. aug. 12. 23:01 UTC

News

Kimball Electronics shares are lower in after-market trading following a quarterly adjusted EPS loss of $0.01, missing expectations of $0.39.

Társak összehasonlítása

Árváltozás

Heron Therapeutics Inc Előrejelzés

Értékelési konszenzus

By TipRanks

Semleges

2 ratings

0

Vétel

2

Tartás

0

Eladás

Hangulat

By Acuity

315 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Nagyon erős bearish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag feletti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat